Source-Omega Reviews DHA Retroconversion Metabolic Dosing Using Algae Oil Omega-

3s as a Fish Oil Substitute

"What all the human omega-3 red blood cell data independently points out is that
DHA is always 3 to 8 fold more abundant than EPA in human blood and tissues, ev
en after prolonged intake of high doses of omega-3s predominantly as EPA," says
company scientist.
Chapel Hill, NC, November 11, 2010 -- Today, Source-Omega ( http://www.source-om
ega.com ) revealed knowledge gained from their review of the omega-3 literature
and published research. "What all the human omega-3 Red Blood Cell data independ
ently point out is that DHA is always 3 to 8 fold more abundant than EPA in huma
n blood and tissues, even after prolonged intake of high doses of omega-3s predo
minantly as EPA," says Scott Doughman, PhD., Chief Scientist at Source-Omega.
Source-Omega ( http://www.source-omega.com ) revealed their discussion, forwardi
ng that composition studies in 1978 proved DHA is naturally the most abundant om
ega-3 form in the human body and blood in comparison to EPA levels in untreated
individuals (Sanders et al., 1978). In 1986, a review by Herold and Kinsella of
human volunteers treated with fish oil omega-3s revealed higher DHA fatty acid c
omposition in red blood cells compared to EPA, despite high EPA intake (Herold a
nd Kinsella, 1986).
Fish oils have been an abundant source of EPA, so fewer studies may have taken i
nto consideration that DHA is the most abundant omega-3 long chain fatty acid be
cause EPA was the main omega-3 given as a fish oil treatment.
When Conquer and Holub published on algae oil DHA treatment ( http://www.source-
omega.com ) of human subjects in 1996, a detailed double-blind randomized placeb
o controlled study, the authors found blood omega-3 parameters consistent with h
umans taking high dosages of fish oil (Conquer and Holub, 1996). The 1996 study
showed RBC increases in both DHA and EPA through accretion of DHA and retroconve
rsion of DHA. Other metabolism studies have shown DHA is also a template that wi
ll provide all the C22, C20, and C18 omega-3s needed in the body through retroco
nversion, say Source-Omega scientists.
DHA delivers saturation levels of omega-3s to RBC membranes when the DHA dosage
( http://www.source-omega.com ) for adult clinical use begins with 1.0 g to 1.2
g DHA per day, which company results, or previous published studies show can pro
vide saturation levels of omega-3s within 90 days (Arterburn et al., 2008).
The scientific literature shows high-dose DHA derived from microalgae lowers hyp
ertriglyceridemia after 90 days of treatment, by up to 26 percent with at least
1 g DHA daily (reviewed by Ryan et al., 2009). With a safe, effective dosage ran
ge for any adult, the GRAS safety registration of algae oil and the dosage range
have been positively ruled-upon, as such, by several international regulatory b
odies.
"The summary of these historical studies together suggest 'directional omega-3 m
etabolism',( http://www.source-omega.com ) where fish oil is 'uphill' and algae
oil is 'downhill'. EPA intake leads to multistep synthesis to DHA with fish oil.
DHA intake leads to a single step retroconversion to EPA with algae oil. The bo
dy knows how to balance its final levels from each direction, but 'downhill' app
ears more efficient at high omega-3 doses," said Doughman.
Each method then flows towards a somewhat pre-defined homeostatic balance of cel
lular and tissue specific omega-3 compositions, the data suggest.
Since the DHA retroconvertion dosing strategy is the opposite of fish oil, Sourc
e-Omega's ( http://www.source-omega.com ) patent pending claims are on the dosag
e use and method of 1200 mg DHA + 40 mg EPA per day as metabolically ideal for c
ertain health claims and postprandial triglyceride lowering benefits [References
Available upon request from Source-Omega].
About Source-Omega:
Source-Omega, LLC ( http://www.source-omega.com ) is headquartered in Chapel Hil
l, North Carolina, near the Research Triangle Park. It was founded in 2007 and s
pecializes in the international marketplace for manufacturing, branding, private
labeling and globalization of algae oil nutritional products under the name and
formula Pure Oneâ ¢, the Next Generation Plant Based Omega-3â ¢ for their Omega-3 DHA Ther
pyâ ¢, for clinics offering triglyceride lowering plasma lipids management programs an
d for pregnancy, nursing and family care.
Press & Media Contact:
Gene Wolf
Source-Omega, LLC
52 Norwood Rd
Chapel Hill, NC 27516 USA
919-360-5275
info@source-omega.com
http://www.source-omega.com